Prostate cancer organoids pave way towards precision oncology
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
Removing stress hormones in mouse models restored proper function to immune cells and epithelial cells, pointing to new Crohn's treatments.
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
The antihypertensive drug candesartan cilexetil reduced matrisomal protein accumulation in mice with cerebral small vessel disease.
The new group of molecules can be chemically altered, showing potential for the development of effective antibiotics with few side effects.
An experimental drug for liver cancer and Dasatinib, approved for chronic myeloid leukaemia could be repurposed to treat Alzheimer's disease.
The study paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.
Scientists targeted a mouse's own cells using a synthetic molecule called EEZE, presenting a novel way to treat pneumonia.
Groundbreaking study succeeded in the intranasal delivery of an anti-depressant peptide-based drug to the brain in mouse models.
A new study claims that future COVID-19 vaccines should activate T cells to attack infected cells expressing replication proteins.
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
The team will receive $2 million over five years to investigate the CA2 brain region for the development of neurological therapies.